Maldonado VJA, Ocampo AMA, Cortés GNL, Acosta AJC, Chávez Carbajal JF, Álvarez AC, Ortiz González MJ

Language: Spanish
References: 25
Page: 191-196
PDF size: 274.60 Kb.

ABSTRACT

Background: Obesity, insulin resistance and atherogenic dyslipidemia represent the main health problems and they are associated with adverse cardiovascular events.
Objective: To determine the insulin resistance index in obese premenopausal women with atherogenic dyslipidemia and non-atherogenic.
Material and Methods: We conducted an observational, descriptive, prospective and cross-sectional study of 125 obese premenopausal women. Age, blood pressure, body mass index, abdominal circumference, body fat percentage, basal glucose and insulin, oral glucose tolerance test, lipid profile and Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) were recorded in the study. Statistical analyses: Student unpaired t test, mean ± SEM and the level of significance was accepted at p ‹ 0.05.
Results: The group with non-atherogenic dyslipidemia had less BMI (p ‹ 0.05) and abdominal circumference (p ‹ 0.05) than the control group normolipidemic. The group with atherogenic dyslipidemia showed a higher systolic blood pressure (p ‹ 0.05), greater levels of glucose basal (p ‹ 0.05), glucose at 2 hours post-load (p ‹ 0.05) and a higher HOMA-IR (3.6 ± 0.4 vs. 2.5 ± 0.6) than the control group normolipidemic.
Conclusions: The BMI and the abdominal circumference not showed relation with the metabolic profile between the studied groups. Obesity and insulin resistance are associated with higher risk for to develop hypertension and type 2 diabetes in the group with atherogenic dyslipidemia. Whereas, the group with non-atherogenic dyslipidemia is at lower risk despite being obese.

REFERENCES

1. Encuesta Nacional de Salud y Nutrición. ENSANUT 2006.

2. Bloomgarden ZT. Insulin Resistance, Dyslipidemia, and Cardiovascular Disease. Diabetes Care 2007;30(8):2164-70.

3. Genoud M, Wietlisbach V, Feihl F, Mermod A, et al. Surrogate Markers for Atherosclerosis in Overweight Subjects with Atherogenic Dyslipidemia: The GEMS Project. Angiology 2008;59(4):484-92.

4. Jensen K. Role of Body Fat Distribution and the Metabolic Complications of Obesity. J Clin Endocrinol Metab 2008;93(11):Suppl 1 s57-s63.

5. Vinik AI. The Metabolic Basis of Atherogenic Dyslipidemia. Clinical Cornerstone 2005;7[2/3]:27-35.

6. Grundy. Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance. Clin Cornerstone 2006;8:Suppl 1:S21-7.

7. Pascot A, Lemieux I, Prud’homme D, Tremblay A, et al. Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity. J Lipid Res 2001;42:2007-14.

8. Kadowaki T, Hara K, Yamauchi T,Terauchi Y, et al. Molecular Mechanism of Insulin Resistance and Obesity. Exp Biol Med 2003;228:1111-17.

9. Nieves DJ, Cnop M, Retzlaff B, Walden, et al. The Atherogenic Lipoprotein Profile Associated With Obesity and Insulin Resistance Is Largely Attributable to Intra-Abdominal Fat. Diabetes 2003;52:172-79.

10. McLaughlin T, Allison G, Abbasi F, Lamendola C, Reaven GM. Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. Metabolism 2004;53:495-99.

11. Saely CH, Aczel S, Marte T, Langer P, et al. The Metabolic Syndrome, Insulin Resistance, and Cardiovascular Risk in Diabetic and Nondiabetic Patients. J Clin Endocrinol Metab 2005;90:5698-703.

12. Marsh JB. Lipoprotein metabolism in obesity and diabetes: insights from stable isotope kinetic studies in humans. Nutr Rev 2003;61:363-75.

13. Bittner V. Perspectives on Dyslipidemia and Coronary Heart Disease in Women. J Am Coll Cardiol 2005;46:1628-35.

14. Barrett CE, Giardina EGV, Gitt AK, Gudat U, et al. Women and heart disease: the role of diabetes and hyperglycemia. Arch Intern Med 2004;164:934-42.

15. Nicklas BJ, Penninx BW, Ryan AS, Berman DM, et al. Visceral Adipose Tissue Cutoffs Associated With Metabolic Risk Factors for Coronary Heart Disease in Women. Diabetes Care 2003;26:1413-20.

16. Chobanian AV, Bakris GL, Black HR, Cushman WC, et al. National Heart, Lung, and Blood Institute; National, High Blood Pressure, Education Program, Coordination, Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Hypertension 2003;42:1206-52.

17. Standards of Medical Care in Diabetes- 2008. American Diabetes Association. Diabetes Care 2008;31:S12-S54.

18. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation and Treatment of High Cholesterol. JAMA 2001;285:2486-97.

19. National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation 2002;106:3143-421.

20. Wallace TM, Levy JC, Matthews DR. Use and Abuse of HOMA Modeling. Diabetes Care 2004;27:1487-95.

21. Aguilar Salinas CA, Olaiz G, Valles V, Torres JM, et al. High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a mexican nationwide survey. J Lipid Res 2001;42(8):1298-307.

22. Reaven GM. Insulin Resistance/Compensatory Hyperinsulinemia, Essential Hypertension, and Cardiovascular Disease. J Clin Endocrinol Metab 2003;88(6):2399-403.

23. Balkrishna M, Singh MD, Jawahar L, Mehta L. Interactions Between the Renin-Angiotensin System and Dyslipidemia. Relevance in the Therapy of Hypertension and Coronary Heart Disease. Arch Intern Med 2003;163:1296-304.

24. Sesso HD, Buring JE, Chown MJ, Ridke PM, Gaziano JM. A Prospective Study of Plasma Lipid Levels and Hypertension in Women. Arch Intern Med 2005;165:2420-27.

25. Philip Barter, Ruth McPherson Y, Kijoung Song, Antero Kesäniemi Y, et al. Serum insulin and inflammatory markers in overweight individuals with and without dyslipidemia. J Clin Endocrin Metab 2007;92:2045-49.